(3.238.96.184) 您好!臺灣時間:2021/05/08 04:36
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

: 
twitterline
研究生:林湣萱
研究生(外文):Min-Hsuan Lin
論文名稱:探討乙胺嘧啶對非小細胞肺癌的抗癌效果
論文名稱(外文):The anti-cancer efficacy of pyrimethamine on non-small cell lung cancer
指導教授:林季千
指導教授(外文):CHI-CHEN LIN
口試委員:陳樺翰陳與國
口試委員(外文):HUA-HAN CHENYU-GUO CHEN
口試日期:2016-07-15
學位類別:碩士
校院名稱:國立中興大學
系所名稱:生命科學院碩士在職專班
學門:生命科學學門
學類:生物學類
論文種類:學術論文
論文出版年:2016
畢業學年度:104
語文別:中文
論文頁數:22
中文關鍵詞:非小細胞肺癌乙胺嘧啶細胞凋亡細胞自噬
外文關鍵詞:Non small cell lung cancersPyrimethamineapoptosisautophagy
相關次數:
  • 被引用被引用:0
  • 點閱點閱:48
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:7
  • 收藏至我的研究室書目清單書目收藏:0
目前已有許多腫瘤的研究指出,乙胺嘧啶(PYR)不論在體內或體外的試驗都具有抗腫瘤的效果,但唯獨沒有關於非小細胞肺癌(NSCLC)的研究。因此在本研究中,我們證明了PYR可以導致非小細胞肺癌的細胞株A549細胞存活率下降,並且可誘導A549細胞的G1期細胞產生停滯,以及大量細胞在sub-G1期的堆積。利用Annexin V和PI雙重染色顯示,在PYR作用下的A549細胞會發生凋亡的情形,證實PYR除了可以誘導細胞在sub-G1期堆積外,此外PYR還可以使A549產生pro-survival細胞自噬。綜合我們的研究結果顯示,PYR可以誘導細胞凋亡,同時也將誘導細胞產生自噬的狀況,未來可將PYR用來化療或治療非小細胞肺癌。

Despite several studies had reported the anti-tumor effect of Pyrimethamine (PYR) in vitro and in vivo in many tumors, there is none about non-small cell lung cancer (NSCLC). In this study, we demonstrated that PYR reduces the cell viability of NSCLC cell lines A549 and induces G1 phase arrest in cells. Double staining of Annexin V and PI indicated that PYR could induce apoptosis in A549 cell, PYR induces sub-G1 phase accumulation. Furthermore, PYR can also induce the pro-survival autophagy in A549 cells. These results suggested PYR induces G1 phase arrest apoptosis to affect the proliferation of A549 cells. PYR also induces the pro-survival autophagy to maintain A549 survival. In summary, our findings showed that PYR promotes intrinsic apoptosis by inducing apoptotic protein activation and can also induces autophagy, suggesting PYR may be considered as chemo-prevention or treatment NSCLC.

目次
摘要 i
Abstract ii
目次 iii
圖表目次 v
縮寫表 v
第一章 緒論 1
一、 肺癌(Lung cancer) 1
二、 乙胺嘧啶之簡介(an introduction of Pyrimethamine) 3
三、 細胞週期(Cell cycle)3
四、 細胞凋亡(Apoptosis) 3
五、 細胞自噬(Autophagy) 6
第二章 研究動機 7
第三章 實驗材料與方法 8
一、 方法步驟 8
1. 細胞繼代培養(subculture of cells)8
2. 計算細胞數 8
二、 細胞存活率檢測(MTT assay) 9
三、 細胞凋亡分析(Annexin V/PI staining assay) 10
四、 細胞週期分析(Cell Cycle assay)10
五、 酸性囊泡器檢測(Acidic vesicular organelles detection) 11
六、 分析與統計方法(Statistical analyses)11
第四章 結果 12
一、 Pyrimethamine (PYR)能有效抑制A549人類肺癌細胞生長作用 12
二、 Pyrimethamine (PYR) 對A549人類肺癌細胞生長抑制走向細胞凋亡主導之型式 12
三、 Pyrimethamine (PYR) 對A549人類肺癌細胞之細胞週期影響 12
四、 Pyrimethamine (PYR) 對A549人類肺癌細胞之酸性囊泡器檢測 12
第五章 研究討論 14
第六章 參考文獻 16
第七章 實驗結果圖 19
圖一、Pyrimethamine對於非小細胞肺癌A549細胞之增生作用影響 19
圖二、Pyrimethamine對於非小細胞肺癌A549之細胞凋亡的影響 20
圖三、Pyrimethamine對於非小細胞肺癌A549之細胞週期分佈 21
圖四、Pyrimethamine對於非小細胞肺癌A549之酸性囊泡器檢測 22

圖表目次
附圖 1主要癌症死亡原因 2
附圖 2半胱氨酸蛋白酶(Procaspases)活化途徑 2
附圖 3凋亡途徑與內源性凋亡途徑 5
附圖 4凋亡蛋白酶活化途徑 5


1.Pilotti, V., et al., Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. (0921-299X (Print)).
2.Molina, J.R., et al., Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic proceedings. Mayo Clinic, 2008. 83(5): p. 584-594.
3.Pfister, D.G., et al., American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol, 2004. 22(2): p. 330-53.
4.Sridharan, V. and J.D. Schoenfeld, Immune effects of targeted radiation therapy for cancer. Discov Med, 2015. 19(104): p. 219-28.
5.Horwitz, S.B., Taxol (paclitaxel): mechanisms of action. (0923-7534 (Print)).
6.Oyaizu, H., et al., A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis. (1522-4724 (Print)).
7.Rajapakse, S., et al., Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathogens and Global Health, 2013. 107(4): p. 162-169.
8.Wettingfeld, R.F., J. Rowe, and D.E. Eyles, TREATMENT OF TOXOPLASMOSIS WITH PYRIMETHAMINE (DARAPRIM) AND TRIPLE SULFONAMIDE*. Annals of Internal Medicine, 1956. 44(3): p. 557-564.
9.Falade, C.O., et al., Comparative efficacy of halofantrine, chloroquine and sulfadoxine-pyrimethamine for treatment of acute uncomplicated falciparum malaria in Nigerian children. Transactions of The Royal Society of Tropical Medicine and Hygiene, 1997. 91(1): p. 58-62.
10.Looareesuwan, S., et al., Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. The American journal of tropical medicine and hygiene, 1996. 54(1): p. 62-66.
11.Giammarioli, A.M., et al., Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res, 2008. 68(13): p. 5291-300.
12.Hooft van Huijsduijnen, R., et al., Anticancer Properties of Distinct Antimalarial Drug Classes. PLoS ONE, 2013. 8(12): p. e82962.
13.Pierdominici, M., et al., Pyrimethamine (2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine) induces apoptosis of freshly isolated human T lymphocytes, bypassing CD95/Fas molecule but involving its intrinsic pathway. (0022-3565 (Print)).
14.Lee, Won-Jun.IGF-I Exerts an Anti-inflammatory Effect on Skeletal Muscle Cells through Down-regulation of TLR4 Signaling. The Korean Association of Immunobiologists Volume 11, Issue 4 2011, pp.223-226.
15.Nanni, S., et al., Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. The Journal of Clinical Investigation, 2002. 110(2): p. 219-227.
16.Tian, X., B. Chen, and X. Liu, Telomere and Telomerase as Targets for Cancer Therapy. Applied Biochemistry and Biotechnology, 2010. 160(5): p. 1460-1472.
17.Graña, X. and E.P. Reddy, Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 1995. 11(2): p. 211-219.
18.Serrano,M.,Haanon,G.J.&Beach,D..A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.Nature(Lond) 366:704-707
19.Elmore, S., Apoptosis: A Review of Programmed Cell Death. Toxicologic pathology, 2007. 35(4): p. 495-516.
20.Fuchs, Y. and H. Steller, Programmed Cell Death in Animal Development and Disease. Cell, 2011. 147(4): p. 742-758.
21.Sathasivam, S., P.J. Ince Pg Fau - Shaw, and P.J. Shaw, Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. (0305-1846 (Print)).
22.Roshal, M., V. Zhu Y Fau - Planelles, and V. Planelles, Apoptosis in AIDS. (1360-8185 (Print)).
23.Famularo, G., S. De Simone C Fau - Marcellini, and S. Marcellini, Apoptosis: mechanisms and relation to AIDS. (0306-9877 (Print)).
24.Wong, R.S.Y., Apoptosis in cancer: from pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research : CR, 2011. 30(1): p. 87-87.
25.Indran, I.R., et al., Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2011. 1807(6): p. 735-745.
26.Brown, J.M. and L.D. Attardi, The role of apoptosis in cancer development and treatment response. Nat Rev Cancer, 2005. 5(3): p. 231-237.
27.Proudfoot, D., et al., Apoptosis Regulates Human Vascular Calcification In Vitro : Evidence for Initiation of Vascular Calcification by Apoptotic Bodies. Circulation Research, 2000. 87(11): p. 1055-1062.
28.Maran, J.P., B. Priya, and C.V. Nivetha, Optimization of ultrasound-assisted extraction of natural pigments from Bougainvillea glabra flowers. Industrial Crops and Products, 2015. 63: p. 182-189.
29.Lavrik, I., A. Golks, and P.H. Krammer, Death receptor signaling. J Cell Sci, 2005. 118(Pt 2): p. 265-7.
30.Jing, K. and K. Lim, Why is autophagy important in human diseases? Exp Mol Med, 2012. 44(2): p. 69-72.
31.Rabinowitz, J.D. and E. White, Autophagy and Metabolism. Science, 2010. 330(6009): p. 1344-1348.
32.Jaishy, B. and E.D.A.-O.h.o.o. Abel, Lipids, Lysosomes and Autophagy. LID - jlr.R067520 [pii]. (1539-7262 (Electronic)).
33.He, C. and D.J. Klionsky, Regulation Mechanisms and Signaling Pathways of Autophagy. Annual review of genetics, 2009. 43: p. 67-93.
34.Glick, D., S. Barth, and K.F. Macleod, Autophagy: cellular and molecular mechanisms. The Journal of pathology, 2010. 221(1): p. 3-12.
35.衛生福利部http://www.mohw.gov.tw/news/531349778.
36.Chen, K.L., et al., Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. (1872-7980 (Electronic)).
37.James, S.J., et al., Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr, 2003. 133(11 Suppl 1): p. 3740s-3747s.
38.Huang, R.F., et al., Folate deficiency induces a cell cycle-specific apoptosis in HepG2 cells. J Nutr, 1999. 129(1): p. 25-31.



QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔